We are live on
!
Find out more
Federated Hermes Portfolio holdings
AUM
$69.6B
1-Year Est. Return
42.52%
This Fund
S&P 500
This Quarter
Est. Return
+5%
1 Year Est. Return
+42.52%
3 Year Est. Return
+132.48%
5 Year Est. Return
+152.58%
10 Year Est. Return
+652.43%
AUM
$40.3B
AUM Growth
+$535M
(+1.3%)
Cap. Flow
-$468M
Cap. Flow
% of AUM
-1.16%
Top 10 Holdings %
Top 10 Hldgs %
15.78%
Holding
2,279
New
170
Increased
711
Reduced
1,071
Closed
189
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amgen
AMGN
|
+$178M |
| 2 |
LyondellBasell Industries
LYB
|
+$133M |
| 3 |
AT&T
T
|
+$124M |
| 4 |
Stanley Black & Decker
SWK
|
+$101M |
| 5 |
Pfizer
PFE
|
+$93.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Clorox
CLX
|
+$229M |
| 2 |
Gilead Sciences
GILD
|
+$164M |
| 3 |
Broadcom
AVGO
|
+$149M |
| 4 |
KeyCorp
KEY
|
+$145M |
| 5 |
Darden Restaurants
DRI
|
+$125M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 20.22% |
| 2 | Technology | 14.47% |
| 3 | Financials | 10.84% |
| 4 | Industrials | 9.01% |
| 5 | Consumer Discretionary | 8.84% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1876
Shell
SHEL
$283B
| $6.34K | ﹤0.01% |
105
| – | – |
|
1877
Astrana Health
ASTH
$1.9B
| $6.1K | ﹤0.01% |
+193
| New | +$6.62K |
|
1878
KE Holdings
BEKE
$17.9B
| $5.99K | ﹤0.01% |
403
| – | – |
|
1879
CAE Inc
CAE
$7.63B
| $5.8K | ﹤0.01% |
259
+30
| +13% | +$664 |
|
1880
Andersons Inc
ANDE
$2.42B
| $5.72K | ﹤0.01% |
124
-35
| -22% | -$1.46K |
|
1881
iShares MSCI Japan Value ETF
EWJV
$788M
| $5.53K | ﹤0.01% |
202
| – | – |
|
|
BELFB
1882
Bel Fuse Inc Class B
BELFB
$3.35B
| $5.45K | ﹤0.01% |
95
-69
| -42% | -$3.16K |
|
|
REFI
1883
Chicago Atlantic Real Estate Finance
REFI
$280M
| $5.44K | ﹤0.01% |
+359
| New | +$5.21K |
|
1884
Blackstone
BX
$95.1B
| $5.39K | ﹤0.01% |
58
| – | – |
|
1885
Sensus Healthcare
SRTS
$50.7M
| $5.26K | ﹤0.01% |
1,670
+1,061
| +174% | +$3.83K |
|
1886
Elastic
ESTC
$8.94B
| $5.19K | ﹤0.01% |
81
| – | – |
|
1887
QuantumScape Corp
QS
$3.11B
| $5.18K | ﹤0.01% |
648
+113
| +21% | +$786 |
|
1888
Universal Electronics
UEIC
$65.5M
| $5.18K | ﹤0.01% |
538
+263
| +96% | +$2.44K |
|
1889
Digi International
DGII
$2.6B
| $5.16K | ﹤0.01% |
131
+29
| +28% | +$998 |
|
1890
Alpha Metallurgical Resources
AMR
$2.39B
| $5.09K | ﹤0.01% |
31
-108
| -78% | -$16.5K |
|
1891
IBEX
IBEX
$542M
| $5.07K | ﹤0.01% |
239
-17
| -7% | -$363 |
|
1892
Hovnanian Enterprises
HOV
$705M
| $4.96K | ﹤0.01% |
+50
| New | +$4.12K |
|
1893
Center Bancorp
CNOB
$1.6B
| $4.89K | ﹤0.01% |
+295
| New | +$4.61K |
|
1894
Dillards
DDS
$10B
| $4.89K | ﹤0.01% |
15
-166
| -92% | -$50.8K |
|
|
PRDS
1895
DELISTED
Pardes Biosciences, Inc. Common Stock
PRDS
| $4.84K | ﹤0.01% |
+2,677
| New | +$4.89K |
|
1896
Quad
QUAD
$492M
| $4.79K | ﹤0.01% |
1,273
-421
| -25% | -$1.52K |
|
1897
TG Therapeutics
TGTX
$8.12B
| $4.72K | ﹤0.01% |
190
+1
| +0.5% | +$26 |
|
|
FSFG
1898
DELISTED
First Savings Financial Group
FSFG
| $4.66K | ﹤0.01% |
352
| – | – |
|
1899
Bioventus
BVS
$888M
| $4.52K | ﹤0.01% |
1,565
-2,616
| -63% | -$5.02K |
|
|
SNCR
1900
DELISTED
Synchronoss Technologies
SNCR
| $4.44K | ﹤0.01% |
530
-18
| -3% | -$152 |
|
Similar funds
Federated Hermes's Q2 2023 Portfolio in Review
As of Q2 2023, Federated Hermes held 2,279 positions worth $40.3B, up 1.3% from $39.7B the previous quarter. Its ten largest holdings account for 16% of the portfolio.
Federated Hermes's Q2 2023 filing shows 170 new, 711 increased, 1,071 reduced and 189 closed positions. Its largest new stake was HashiCorp, Inc. Class A Common Stock: 1,317,400 shares worth $34.5M. The largest sale was Clorox, an estimated $229M.
By sector, the portfolio is most concentrated in Healthcare at 20% of assets, up from 20% a quarter earlier, followed by Technology and Financials.
- Federated Hermes's largest Q2 2023 buy was HashiCorp, Inc. Class A Common Stock: 1,317,400 shares worth $34.5M.
- Federated Hermes added most to Amgen in Q2 2023, an estimated $178M increase.
- Federated Hermes's biggest Q2 2023 reduction was Clorox, cutting an estimated $229M.
- Federated Hermes fully exited Prometheus Biosciences, Inc. Common Stock in Q2 2023, selling an estimated $55.4M.
- Federated Hermes's ten largest holdings make up 16% of its $40.3B portfolio in Q2 2023.
- Federated Hermes opened 170 new positions and closed 189 in Q2 2023.
- Federated Hermes's portfolio value rose 1.3% quarter-over-quarter to $40.3B.
Based on Federated Hermes's 13F filing for Q2 2023, filed 14 Aug 2023.